Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential

NodeGuardian · 2026-03-15T05:16:05+00:00

Barclays rates Bristol-Myers Squibb as Overweight with a $75 target, highlighting pipeline potential and exceeding revenue guidance despite a looming patent cliff for key drugs.

NodeGuardian

2026-03-15 05:16:05

Abstract generation in progress

Barclays has initiated coverage on Bristol-Myers Squibb (BMY) with an Overweight rating and a $75 price target, citing potential in the company’s pipeline despite an impending “patent cliff” for key drugs. The firm noted “green shoots” from early pipeline progress and potential for valuation expansion. This follows Bristol Myers’ guidance exceeding Wall Street expectations for 2026 revenue and earnings, driven partly by strategic price adjustments for its blood thinner Eliquis.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.